 |
 | Interpretation of Antibiotic Susceptibility Testing |
| |  | MIC-to-MBC Ratio |
| | | Fractional Inhibitory Concentration (FIC) |
| | | Fractional Bactericidal Concentration (FBC) |
| | | Antibiotic Serum Level-to-MIC Ratio |
| | | Inhibitory Quotient of Ellner and Neu |
| | | Categorical Comparison of Antibiotic Susceptibility Test Results with the Reference Results |
| | | Essential Agreement Between Antibiotic Susceptibility Test Results with Reference Results |
| | | D Zone Test for Inducible Clindamycin Resistance in Methicillin Resistant Staphylococcus Aureus (MRSA) |
| | | Patterns of Antibiotic Interaction (Additive, Synergistic, Antagonistic) During Disk Diffusion Testing |
| | | Inoculum Effect |
| | | Minimum Lethal Concentration (MLC) of Metronidazole for Trichomonas vaginalis |
| Dosing Antibiotics in Renal Failure |
| |  | Maintenance Dosage Fraction Based on Estimated Drug Clearance |
| | | Maintenance Dosage Fraction Based on the Fractional Rate Constant |
| | | Dosing Aminoglycosides in Renal Failure Using the Method of Sarubbi and Hull |
| | | Equation of Matzke et al for Dosing Vancomycin in Renal Failure |
| | | Dosing Amantadine in Renal Failure |
| | | Foscarnet Dose for CMV Retinitis in Renal Dysfunction |
| Dosing Antibiotics in Special Situations |
| | | Dosing Aminoglycosides in Obese Patients |
| | | Dosing Aminoglycosides in Underweight Patients |
| | | Contraindications to Extended Interval Aminoglycoside Dosing (EIAD) |
| | | Extended Interval Aminoglycoside Administration Using the Lower Dosage |
| | | Extended Interval Aminoglycoside Administration Using the Higher Dosage |
| Dosing Aminoglycosides Using the Method of Sawchuk and Zaske |
| | | Determine the Loading Dose |
| | | Calculate the elimination rate constant (k) |
| | | Estimate the Volume of Distribution |
| | | Determine the Dosage Interval |
| | | Determine the Maintenance Dose |
| | | Calculate the New C(min-ss) |
| Tuberculosis |
| | | Preventive Therapy for Persons with Positive Tuberculin Skin Test (PPD) Reactions |
| | | Indications for Prophylaxis to Mycobacterium tuberculosis in Solid Organ Transplant Recipients |
| | | Indications for Prophylaxis to Mycobacterium tuberculosis in Patients Taking Infliximab |
| | | Indications for Considering the Administration of BCG (Bacille Calmette-Guerin) Vaccine |
| | | Treatment Algorithm of the ATS, CDC and IDSA for a Patient with a High Clinical Suspicion for Active Tuberculosis |
| | | Treatment Algorithm of the ATS, CDC, and IDSA for a Patient with Possible Tuberculosis and Negative Initial Sputum Smears |
| | | Length of Antituberculous Therapy for a Patient with Extrapulmonary Tuberculosis |
| | | Management of an Interruption in Antituberculous Therapy |
| Rabies |
| | | Rabies Post-Exposure Prophylaxis |
| | | Algorithm for Rabies Exposure Management |
| | | Complications of Suwansrinon et al Associated with Injecting Rabies Immunoglobulin Into a Bite Wound |
| | | Exposure to Bats and Rabies Prophylaxis |
| Prevention and Therapy of Pneumococcal Infections |
| | | Recommendations for Pneumococcal Vaccination |
| | | Recommendations for Revaccination with the Pneumococcal Vaccine |
| Prophylactic Antibiotic Regimens |
| | | Prophylaxis for Bacterial Endocarditis with Dental Procedures in 1997 |
| | | Revised Recommendations for Prophylaxis to Prevent Bacterial Endocarditis After Dental Procedures |
| | | Prophylaxis for Bacterial Endocarditis with Surgical Non-Dental Procedures |
| | | Algorithm for Prophylaxis in Suspected Mitral Valve Prolapse |
| | | Prophylaxis for Dental Procedures in Patients with Total Joint Replacements |
| | | Prophylactic Antibiotics before Biliary Tract Surgery |
| | | Prophylactic Antibiotic Therapy After Dog Bites |
| | | Prophylactic Antibiotic Regimen of Such and Runyon for a Patient with Cirrhosis and Ascites |
| | | Recommendations of Simpson et al for Antibiotic Prophylaxis and Therapy in a Patient with a Gunshot-Related Fracture |
| Prevention and Therapy of Influenza |
| | | Chemoprophylaxis to Influenza A With Amantadine or Ramantadine |
| | | Recommendations for Influenza Vaccination |
| | | Contraindications to the Use of the Intranasal Live Influenza Vaccine (Flumist) |
| | | Criteria of Freedman and Leder for a Patient Who Is Inadequately Vaccinated Against Influenza |
| | | Use of Oseltamivir to Treat or Prevent Influenza |
| Prevention and Management of Meningococcal Disease |
| | | Chemoprophylaxis for Meningococcal Exposure |
| | | Recommendations for Meningococcal Vaccination |
| HIV Postexposure Prophylaxis |
| | | 1998 CDC Recommendations for Postexposure Prophylaxis in Health Care Workers |
| Home and Outpatient Antibiotic Therapy |
| | | Selection of Patients for Outpatient Parenteral Antibiotic Therapy |
| | | Indications for Use of an Infusion Pump by a Patient Receiving Home Parenteral Antibiotic Therapy |
| | | Criteria for Outpatient Antibiotic Therapy for a Patient with Bacterial Meningitis |
| Malaria Prophylaxis and Therapy |
| | | Contraindications to the Use of Mefloquine for Malaria Prophylaxis |
| | | Use of Doxycycline for Malaria Prophylaxis |
| | | Algorithm of Connor for Antimalarial Prophylaxis Based on Sensitivity in Area |
| | | Reasons Travelers Give for Not Taking Malaria Prophylaxis |
| | | Dosing Malarone (Atovaquone and Proguanil HCl) for Prophylaxis or Therapy of Plasmodium falciparum |
| | | WHO Patterns of Drug Resistance in Malaria |
| | | Identification of Plasmodium falciparum Malaria Resistant to Sulfadoxine and Pyrimethamine Therapy Using Molecular Markers of DHFR and DHPS |
| | | Genotype Resistance Index (GRI) and Genotype Failure Index (GFI) for Epidemiologic Studies of Drug Resistant Plasmodium falciparum |
| | | Classifying the Risk of Malaria Transmission for a Traveler |
| | | Stand-By Emergency Treatment (SBET) for Malaria |
| | | Contraindications for Primaquine Therapy to Eliminate the Persistent Liver Stages of Plasmodium vivax or ovale |
| Prevention and Therapy of Anthrax |
| | | Postexposure Prophylaxis for Anthrax |
| Antibiotic Resistance |
| | | Predictive Index for Antibiotic Resistance in Gram-Negative Bacteremia |
| | | Situations Where Vancomycin Use Should Be Avoided to Minimize Emergence of Drug Resistant Strains |
| | | Centers for Disease Control (CDC) 12 Step Program to Prevent Antimicrobial Resistance Among Hospitalized Patients |
| | | Prediction Rule of Tacconelli et al for Identifying Patients at Risk for Vancomycin Resistant Enterococci on Admission to a Hospital |
| | | Risk Factors of Lynch and Martinez for Macrolide Resistance in Streptococcus pneumoniae |
| | | Risk Factors of Lautenbach et al for Fluoroquinolone Resistance in Nosocomial Infections with Escherichia coli and Klebsiella pneumoniae |
| | | Classification Tree of El Solh et al for Predicting Antibiotic Resistance in a Pneumonia Affecting an Elderly Institutionalized Patient |
| | | Risk Factors of Niederman et al for Multidrug Resistant Bacterial Pneumonia Acquired in a Health Care Setting |
| | | Risk Factors of Pfaller and Segreti for Detecting a Patient with Bacteria Producing an Extended-Spectrum Beta-Lactamase |
| | | Risk Factors for Hospital and Community Acquired Methicillin or Oxacillin Resistant Staphylococcus Aureus (MRSA, ORSA) |
| | | Risk Factors of Ohmagari for Infection with a Multidrug-Resistant Pseudomonas aeruginosa in a Patient with Cancer |
| | | Risk Factors of Rentz et al for Infection with Ampicillin Resistant Bacteria in a Newborn Infant Receiving Group B Streptococcal Prophylaxis |
| | | Vancomycin Tolerance in a Cancer Patient with a Gram Positive Bacterial Infection |
| | | Criteria of Paterson for Multidrug Resistant and Panresistant Pseudomonas aeruginosa |
| | | When To Suspect That a Patient May Have Drug-Resistant Mycobacterium tuberculosis |
| | | WHO and CDC Definition for Extensively Drug-Resistant Mycobacterium tuberculosis |
| | | Risk Factors of Ansari et al for Infection with Multidrug-Resistant Stenotrophomonas maltophilia in a Patient with Cancer |
| | | Criteria for Appropriate vs Inappropriate Initial Antimicrobial Therapy |
| | | Risk Facots of Kang et al for Mortality Associated with Bloodstream Infections Caused by Antibiotic-Resistant Gram-Negative Bacilli |
| | | Risk Factors of Tumbarello et al for Suspecting Methicillin-Resistant Staphylococcus aureus Bacteremia in an HIV-Infected Patient |
| | | Risk Factors of Wright et al for a Urinary Tract Infection Caused by a Multidrug Resistant Uropathogen |
| | | Risk Factors of Harris et al for Patient Colonization with an Extended Spectrum Beta-Lactamase Producing Bacteria on ICU Admission |
| | | Criteria of Paterson and Doi for a Gram-Negative Bacillus Showing Extreme Drug Resistance (XDR) |
| | | Risk Factors of DuPont for Infection with a Fluoroquinolone-Resistant Campylobacter Species |
| Allergic and Other Adverse Reactions to Vaccination |
| | | Algorithm for Administering the Measles-Mump-Rubella (MMR) Vaccine in Children with Egg Allergy |
| | | Identification of Patients With a Higher Risk of Adverse Reaction to Japanese Encephalitis (JE) Vaccine |
| | | Categories of Adverse Events Associated with Vaccines |
| | | Vaccines Not Recommended for Immunocompromised Patients |
| | | Factors Suggesting a Causal Association Between a Vaccination and an Adverse Event |
| | | Method of James et al for Administering Influenza Vaccine to a Patient with Egg Allergy |
| | | Features of the Oculorespiratory Syndrome (ORS) Associated with Influenza Vaccination |
| | | Criteria of Scheifele et al for Evaluating an Injection Site Reaction Following Vaccination |
| | | Classification of Woo et al for Extensive Limb Swelling After Immunization |
| | | Evaluating a Patient for Local and Systemic Reactions to a Vaccine |
| | | Local Reactions to Live Measles Virus Vaccine in Previous Recipients of a Killed Measles Virus Vaccine |
| | | Risk of Disease Transmission Associated with a Needle-Free Jet Injector |
| | | Yellow Fever Vaccine-Associated Neurotropic Disease (YEL-AND, Postvaccinal Encephalitis) |
| | | Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD, Postvaccinal Multiple Organ Failure) |
| | | Valid and Invalid Reasons of Lane et al for Not Vaccinating a Child |
| Therapeutic Failure in Treatment of Infectious Diseases |
| | | Therapeutic Failure in the Treatment of Head Lice |
| Prevention and Treatment of Viral Hepatitis |
| | | CDC Recommendations for Treatment with Interferon in Patients with Hepatitis C |
| | | Contraindications for Therapy with Interferon in Viral Hepatitis C |
| | | Recommendations for Vaccination Against Hepatitis A Virus |
| | | Recommendations for Postexposure Prophylaxis to Hepatitis A Virus |
| | | Recommendations for Vaccination Against Hepatitis B Virus |
| | | Initial Dosing of Copegus (Ribavirin) and Pegasys (Interferon alfa-2b) in the Therapy of Chronic Viral Hepatitis C |
| | | Adjusting the Dose of Copegus (Ribavirin) in a Patient with Chronic Viral Hepatitis C |
| | | Adjusting the Dose of Interferon alfa-2b in a Patient with Chronic Viral Hepatitis C |
| | | Algorithm of Fiore for Determining the Need for Immunoprophylaxis After Exposure to Food Prepared By a Food Handler with Hepatitis A |
| Therapy of Human Immunodeficiency Virus (HIV) Infection |
| | | Evaluation of a Patient with HIV Virologic Failure for Drug Regimen Adherence |
| | | Indications for Starting Antiretroviral Therapy in a Patient with Chronic HIV Infection |
| | | Indications to Change an Antiretroviral Therapeutic Regimen |
| | | Hazards of Alcohol and Drug Abuse in a Patient Receiving Antiretroviral Therapy for HIV Infection |
| | | Risk Factors of Mugavero et al for a Patient with HIV Manifesting "No Show" Behavior |
| Route of Antibiotic Administration |
| | | Method of Wong-Beringer et al for Switching from Intravenous to Oral Antibiotic Dosing |
| Prevention and Therapy of Smallpox (Vaccinia) |
| | | Contraindications for the Use of Smallpox Live Vaccinia Virus Vaccine |
| | | Evaluation of the Patient Response to Smallpox Vaccination |
| | | Adverse Reactions Following Smallpox Vaccination |
| | | Contraindications for the Use of Smallpox Vaccine in Patients with Heart Disease |
| Prevention and Treatment of Chickenpox and Herpes Zoster (Varicella Zoster Virus, VZV) |
| | | Indications for Passive Immunization with Varicella Zoster Immune Globulin (VZIG) |
| | | Recommendations for Active Varicella Vaccination |
| Recommendations for Multi-Agent Vaccines |
| | | Recommendations for Vaccination to Measles, Mumps and Rubella |
| | | Contraindications and Precautions for Administration of Diphtheria-Tetanus-Pertussis (DTP) Vaccine |
| Prevention and Management of Tetanus |
| | | Tetanus Prophylaxis in Wound Management |
| Prevention and Management of Lyme's Disease |
| | | Recommendations for Lyme Disease Vaccination |
| | | Management of a Patient with an Attached Tick |
| | | Management of a Patient with Carditis Associated with Lyme Disease |
| Prevention and Therapy of Respiratory Syncytia Virus (RSV) Infections |
| | | The American Academy of Pediatrics (AAP) 1998 Recommendations for Palivizumab and RSV-IGIV to Prevent RSV Infection |
| Allergy to Antibiotics |
| | | Method of Robinson et al for Approaching a Patient with a Suspected Reaction to a Penicillin or Cephalosporin Antibiotic |
| | | Indications for Skin Testing with a Penicillin or Cephalosporin Antibiotic |
| | | Skin Test for Penicillin Allergy |
| | | Oral Desensitization Protocol of Gluckstein and Ruskin for a Patient with a Sensitivity Reaction to Trimethoprim-Sulfamethoxazole |
| | | Intravenous Desensitization Protocol of Ghosal and Taylor for Ceftazidime |
| | | Oral Protocol of Sullivan for Desensitization of a Patient with Allergy to a Beta-Lactam Antibiotic |
| | | Intravenous Desensitization Protocol of Gea-Banachloche and Metcalfe for Ciprofloxacin |
| Barriers to Vaccination |
| | | Factors Associated with Fear of Injection or Fainting Afterwards |
| | | Criteria for the Diagnosis of Blood-Injection-Injury Specific Phobia |
| | | Reasons Identified by Meszaros et al for Why Some Parents Do Not Have Their Children Vaccinated Against Pertussis |
| | | Enabling and Preventing Factors of Friede et al for Vaccination in Developing Countries, with a Modification of the Adversity Index |
| | | Factors of Salmon et al for Identifying Parents Who May Refuse Vaccination for Their Children |
| | | Observations of Mercado on the Vaccination of a Patient with Systemic Lupus Erythematosus (SLE) |
| Prophylaxis Against Opportunistic Organisms in a Patient with HIV Disease |
| | | Indications for Prophylaxis Against Pneumocystis Carinii in a Patient with HIV Disease |
| | | Indications for Prophylaxis Against Mycobacterium avium-intracellulare (MAI) complex Infection in a Patient with HIV Disease |
| | | Indications for Prophylaxis Against Cytomegalovirus (CMV) Retinitis in a Patient with HIV Disease |
| | | Indications for Prophylaxis Against Cryptococcosis in a Patient with HIV Disease |
| | | Indications for Prophylaxis Against Toxoplasmosis in a Patient with HIV Disease |
| | | Indications for Prophylaxis Against Noncryptococcal Fungal Infections in a Patient with HIV Disease |
| Evaluating a Vaccine |
| | | Determining Vaccine Efficacy |
| | | Reasons Why a Vaccine May Not Be Effective in Preventing an Infection |
| Antihelmintic Therapy |
| | | Dosing Albendazole in Hydatid Disease and Neurocysticerosis |
| | | Dosing Thiabendazole for a Patient with a Nematode Infection |
| | | Dosing Ivermectin for a Patient with a Nematode Infection |
| | | Dosing Niclosamide for a Patient with an Intestinal Cestode (Tapeworm) Infection |
| Pneumocystis Carinii (P. jirovecii) Prophylaxis and Therapy |
| | | Indications for Prophylaxis Against Pneumocytis Carinii in an HIV-Negative Patient |
| | | Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) with Trimethoprim Sulfamethoxazole (TMP-SMX) |
| | | Therapy of Pneumocystis Carinii Pneumonia (PCP) with Trimethoprim Sulfamethoxazole (TMP-SMX) |
| Therapy of Bacterial Infections with Trimethoprim-Sulfamethoxazole |
| | | Dosing Trimethoprim-Sulfamethoxazole for Urinary Tract Infection, Acute Otitis and Other Infections in Children |
| Antifungal Therapy |
| | | Risk Factors for Nephrotoxicity Associated with Amphotericin B Deoxycholate Therapy |
| | | Protocol of Kiwan and Anaissie for Treating Invasive Pulmonary Aspergillosis |
| | | Indications of Anaissie et al for Antifungal Therapy in a Cancer Patient at Risk for Fungal Infection |
| | | Algorithm of Spellberg et al for Empirical Antifungal Therapy in a Patient with Known or Suspected Disseminated Candidiasis |
| | | Algorithm of Spellberg et al for Modifying Antifungal Therapy in a Patient with Disseminated Candidiasis |
| | | Risk Factors of Garey et al for Mortality in a Patient Treated with Fluconazole for Candidemia |
| Prevention and Therapy of Bordetella pertussis (Whooping Cough) |
| | | Candidates for Postexposure Prophylaxis to Prevent Pertussis |
| Selective Digestive Tract Decontamination (SDD) |
| | | The Standard Regimen for Selective Digestive Tract Decontamination |
| Urinary Antiseptics |
| | | Determining If Methenamine Is Appropriate for Use as a Urinary Antiseptic Agent |
| Rotavirus Vaccine |
| | | Absolute and Relative Contraindications to Administration of the Live, Oral Rotavirus Vaccine |
| Passive Immunization with Immunoglobulin |
| | | Immunoglobulin Administration Following Exposure to Measles |
| Prevention of Arbovirus Infections |
| | | Contraindications and Precautions for Immunization with Yellow Fever Vaccine |
| | | Indications for Immunization with Yellow Fever Vaccine |
| | | Criteria for a Valid Yellow Fever Vaccination Certificate |
| |
| TOP |